A detailed history of Mitchell Mcleod Pugh & Williams Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Mitchell Mcleod Pugh & Williams Inc holds 11,370 shares of BMY stock, worth $651,842. This represents 0.12% of its overall portfolio holdings.

Number of Shares
11,370
Previous 11,367 0.03%
Holding current value
$651,842
Previous $472,000 24.58%
% of portfolio
0.12%
Previous 0.11%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

BUY
$39.66 - $51.75 $118 - $155
3 Added 0.03%
11,370 $588,000
Q2 2024

Jul 31, 2024

SELL
$40.25 - $52.99 $308,918 - $406,698
-7,675 Reduced 40.31%
11,367 $472,000
Q1 2024

May 01, 2024

BUY
$47.98 - $54.4 $2,878 - $3,264
60 Added 0.32%
19,042 $1.03 Million
Q4 2023

Feb 05, 2024

SELL
$48.48 - $57.85 $9,841 - $11,743
-203 Reduced 1.06%
18,982 $973,000
Q3 2023

Oct 20, 2023

BUY
$57.89 - $64.73 $20,724 - $23,173
358 Added 1.9%
19,185 $1.11 Million
Q2 2023

Aug 08, 2023

SELL
$63.71 - $70.74 $8,473 - $9,408
-133 Reduced 0.7%
18,827 $1.2 Million
Q1 2023

May 10, 2023

SELL
$65.71 - $74.53 $8,213 - $9,316
-125 Reduced 0.65%
18,960 $1.31 Million
Q4 2022

Feb 03, 2023

SELL
$68.48 - $81.09 $69,370 - $82,144
-1,013 Reduced 5.04%
19,085 $1.37 Million
Q3 2022

Nov 07, 2022

SELL
$0.13 - $76.84 $12 - $7,530
-98 Reduced 0.49%
20,098 $1.43 Million
Q2 2022

Nov 18, 2022

BUY
$72.62 - $79.98 $7,116 - $7,838
98 Added 0.49%
20,196 $1.56 Million
Q2 2022

Jul 19, 2022

SELL
$72.62 - $79.98 $41,538 - $45,748
-572 Reduced 2.75%
20,196 $1.56 Million
Q1 2022

Apr 26, 2022

BUY
$61.48 - $73.72 $53,180 - $63,767
865 Added 4.35%
20,768 $1.52 Million
Q4 2021

Feb 02, 2022

BUY
$53.63 - $62.52 $53 - $62
1 Added 0.01%
19,903 $1.24 Million
Q3 2021

Nov 08, 2021

BUY
$59.17 - $69.31 $74,080 - $86,776
1,252 Added 6.71%
19,902 $1.18 Million
Q2 2021

Nov 08, 2021

BUY
$61.91 - $67.42 $4,519 - $4,921
73 Added 0.39%
18,650 $1.25 Million
Q2 2021

Aug 03, 2021

SELL
$61.91 - $67.42 $95,712 - $104,231
-1,546 Reduced 7.68%
18,577 $1.24 Million
Q1 2021

May 12, 2021

BUY
$59.34 - $66.74 $8,841 - $9,944
149 Added 0.75%
20,123 $1.27 Million
Q4 2020

Feb 08, 2021

SELL
$57.74 - $65.43 $1,501 - $1,701
-26 Reduced 0.13%
19,974 $1.24 Million
Q3 2020

Oct 27, 2020

BUY
$57.43 - $63.64 $4,364 - $4,836
76 Added 0.38%
20,000 $1.21 Million
Q2 2020

Jul 17, 2020

BUY
$54.82 - $64.09 $438,560 - $512,720
8,000 Added 67.09%
19,924 $1.17 Million
Q1 2020

Apr 08, 2020

BUY
$46.4 - $67.43 $11,924 - $17,329
257 Added 2.2%
11,924 $665,000
Q4 2019

Jan 08, 2020

BUY
$49.21 - $64.19 $280,595 - $366,011
5,702 Added 95.59%
11,667 $749,000
Q3 2019

Oct 08, 2019

BUY
$42.77 - $50.71 $19,674 - $23,326
460 Added 8.36%
5,965 $302,000
Q2 2019

Jul 09, 2019

BUY
$44.62 - $49.34 $6,693 - $7,401
150 Added 2.8%
5,505 $250,000
Q4 2018

Jan 10, 2019

SELL
$48.76 - $63.23 $24,380 - $31,615
-500 Reduced 8.54%
5,355 $278,000
Q3 2018

Oct 09, 2018

SELL
$55.19 - $62.25 $1,490 - $1,680
-27 Reduced 0.46%
5,855 $363,000
Q2 2018

Jul 13, 2018

BUY
$50.53 - $62.98 $1,364 - $1,700
27 Added 0.46%
5,882 $325,000
Q3 2017

Oct 12, 2017

BUY
$55.23 - $63.74 $323,371 - $373,197
5,855
5,855 $373,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $122B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Mitchell Mcleod Pugh & Williams Inc Portfolio

Follow Mitchell Mcleod Pugh & Williams Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mitchell Mcleod Pugh & Williams Inc, based on Form 13F filings with the SEC.

News

Stay updated on Mitchell Mcleod Pugh & Williams Inc with notifications on news.